Table 2.

HPV prevalences in the tested population (44,146 samples) according to gender and age group

Age groupn samplesHPV-Positive samples% HPV Positivity (95% CI)% HPV Positivity restricted to samples with only urine (95% CI)% HPV Positivity restricted to samples with cervicovaginal swabs (95% CI)a
0–12Women7022.9 (0–6.8)0 (0)10.0 (0–28.6)
Men5600 (0)0 (0)N/A
13Women14321.4 (0–42.9)20.0 (0–55.1)22.2 (0–49.4)
Men100 (0)0N/A
14Women1302015.4 (9.2–21.6)11.1 (0.84–21.4)17.2 (9.5–24.9)
Men1500 (0)0N/A
15Women56312121.5 (18.1–24.9)18.9 (13.5–24.3)23.4 (19.0–27.9)
Men4612.2 (0–6.4)0N/A
16Women98231832.4 (29.5–35.3)29.0 (24.3–33.7)34.4 (30.6–38.2)
Men202146.9 (3.4–10.4)7.1 (3.5–10.7)N/A
17Women1,71567739.5 (37.2–41.8)34.0 (29.9–38.1)42.3 (39.5–45.1)
Men327195.8 (3.3–8.3)5.7 (3.1–8.3)N/A
18Women2,3131,03544.7 (42.7–46.7)39.1 (35.5–42.7)47.3 (44.9–49.7)
Men5465610.3 (7.8–12.8)9.8 (7.3–12.3)N/A
19Women2,3001,15450.2 (48.2–52.2)43.2 (39.5–46.9)53.6 (51.1–56.1)
Men6977711.0 (8.7–13.3)11.1 (8.7–13.5)N/A
20Women2,2371,19253.3 (51.2–55.4)43.1 (39.3–46.9)57.7 (55.2–60.2)
Men7639011.8 (9.5–14.1)11.8 (9.4–14.2)N/A
21Women2,0511,11554.4 (52.2–56.6)44.0 (40.1–47.9)59.7 (57.1–62.3)
Men76510613.9 (11.4–16.4)14.1 (11.6–16.6)N/A
22Women2,0391,09453.7 (51.5–55.9)37.6 (33.6–41.6)60.2 (57.7–62.7)
Men79111314.3 (11.9–16.7)13.9 (11.4–16.4)N/A
23Women1,84989248.2 (45.9–50.5)36.1 (32.0–40.2)53.4 (50.7–56.1)
Men74211115.0 (12.4–17.6)13.8 (11.2–16.4)N/A
24Women1,57570544.8 (42.3–47.3)28.2 (24.0–32.4)51.9 (49.0–54.8)
Men6488613.3 (10.7–15.9)12.5 (9.8–15.2)N/A
25Women1,41858641.3 (38.7–43.9)31.1 (26.7–35.5)46.0 (42.9–49.1)
Men5846811.6 (9.0–14.2)10.3 (7.7–12.9)N/A
26–30Women5,9841,98533.2 (32.0–34.4)19.0 (17.3–20.7)41.1 (39.5–42.7)
Men2,16424911.5 (10.2–12.8)9.6 (8.3–10.9)N/A
31–35Women3,82984622.1 (20.8–23.4)13.5 (11.8–15.228.4 (26.5–30.3)
Men1,121998.8 (7.1–10.5)7.5 (5.8–9.2)N/A
36–40Women2,18142619.5 (17.8–21.2)13.5 (11.2–15.8)23.5 (21.2–25.8)
Men615569.1 (6.8–11.4)8.3 (5.9–10.7)N/A
41–45Women1,06020819.6 (17.2–22.0)16.3 (12.2–20.4)21.2 (18.2–24.2)
Men372277.3 (4.7–9.9)6.1 (3.4–8.8)N/A
46–50Women4678117.3 (13.9–20.7)11.2 (5.5–16.9)19.9 (15.6–24.2)
Men2082210.6 (6.4–14.8)5.9 (2.2–9.6)N/A
51–55Women1954523.1 (17.2–29.0)22.0 (10.5–33.5)23.5 (16.4–30.6)
Men1471711.6 (6.4–16.8)7.6 (2.8–12.4)N/A
56–60Women921718.5 (10.6–26.4)17.9 (3.7–32.1)19.0 (8.9–29.1)
Men1001919.0 (11.3–26.7)12.7 (5.4–20.0)N/A
61+Women731216.4 (7.9–24.9)5.6 (0–16.2)22.4 (10.7–34.1)
Men9955.1 (0.77–9.4)3.9 (0–8.2)N/A
TotalWomen33,13712,53437.8 (37.3–38.3)26.9 (26.1–27.7)43.6 (42.9–44.3)
Men11,0091,23511.2 (10.6–11.8)10.3 (9.7–10.9)N/A

N/A, not applicable.

  • aSamples combining a cervicovaginal swab with urine are included in this category, as their HPV prevalences were similar to the HPV prevalences in cervicovaginal swabs.